Climb Bio (CLYM) Stock Price Target 2026

The average analyst price target for Climb Bio is $25.29, 119.7% above the current price. Of 15 analysts, 15 rate it Buy. Targets range from $9 to $35. The latest change came on Nov 6, 2026, when Wedbush raised its price target on Climb Bio from $25 to $27 and kept an Outperform rating.

The Average Analyst Price Target for Climb Bio is $25.29.

Price Target Range — 7 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

14Buy

Consensus RatingBuy# Analysts15Avg. Consensus PT$25.29Upside to Avg. PT+119.7%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Climb Bio Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 6, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$25→$27
Oct 27, 2026	BTIG	Julian Harrison	Maintained	Buy	$32
Oct 20, 2026	Deutsche Bank	David Hoang	Initiate	Buy	$28
Sep 8, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$18→$25
Sep 8, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$24→$30
Sep 4, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$26→$30
Sep 3, 2026	BTIG	Julian Harrison	PT Raise	Buy	$20→$32
Sep 3, 2026	Baird	Colleen Kusy	PT Raise	Outperform	$21→$25
Aug 24, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$20→$24
Aug 19, 2026	Wedbush	Laura Chico	Maintained	Outperform	$20
Aug 7, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$17→$25
Jul 27, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$17→$20
Jun 24, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Jun 12, 2026	Wedbush	Laura Chico	Maintained	Outperform	$17
Jun 11, 2026	BTIG	Julian Harrison	PT Raise	Buy	$19→$20
Jun 8, 2026	Guggenheim	Yatin Suneja	Initiate	Buy	$35
Jun 8, 2026	BTIG	Julian Harrison	Maintained	Buy	$19
May 12, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$15→$20
May 8, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$15→$17
May 6, 2026	BTIG	Julian Harrison	PT Raise	Buy	$8→$19